RELAPSED

作品数：98被引量：152H指数：7
导出分析报告
相关领域：医药卫生农业科学更多>>
相关作者：关涛苏丽萍马莉赵瑾王晶荣更多>>
相关机构：上海市第一人民医院绍兴文理学院绍兴市人民医院浙江省人民医院更多>>
相关期刊：《Cellular & Molecular Immunology》《Science China(Life Sciences)》《Chinese Journal of Integrative Medicine》《World Journal of Hematology》更多>>
相关基金：国家自然科学基金北京市自然科学基金广东省自然科学基金更多>>
-
在结果中检索

检索结果分析

结果分析中...
共 条 记 录，以下是1-10
全选清除导出
参考文献引证文献引用追踪
视图：
排序：
Granulocyte colony-stimulating factor in neutropenia management after CAR-T cell therapy:A safety and efficacy evaluation in refractory/relapsed B-cell acute lymphoblastic leukemia
《Chinese Medical Journal》2025年第1期111-113,共3页Xinping Cao Meng Zhang Ruiting Guo Xiaomei Zhang Rui Sun Xia Xiao Xue Bai Cuicui Lyu Yedi Pu Juanxia Meng Huan Zhang Haibo Zhu Pengjiang Liu Zhao Wang Yu Zhang Wenyi Lu Hairong Lyu Mingfeng Zhao 
supported by grants from the General Project of the National Natural Science Foundation of China(No.81970180);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022QN030);the Key projects of Tianjin Applied Basic Research and Multi-Investment Fund(No.21JCZDJC01240);the Science and Technology Project of Tianjin Municipal Health Committee(No.TJWJ2022XK018);Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJYXZDXK-056B);Tianjin Municipal Natural Science Foundation(No.22JCQNJC00820);Tianjin Health Research Project(No.TJWJ2023QN027);Tianjin Health Bureau Project(No.ZC20074);Tianjin Key Medical Discipline(Specialty)Construction Project(No.TJWJ2023XK010);Henan Provincial Youth and Middle-aged Health Science and Technology Talents Excellent Youth Program(No.20230273).
To the Editor:After chimeric antigen receptor T(CAR-T)cell therapy,over 90%of patients experience either mild or severe cytopenia,with the prevalence of Grades 3–4 neutropenia ranging from 53%to 94.3%.[1,2]Granulocyt...
关键词：anti inflammatory effects efficacy cytokine release syndrome chimeric antigen receptor T cell therapy NEUTROPENIA granulocyte colony stimulating factor 
Surgical Treatment of Relapsed Clubfoot Using the Ilizarov Method: Anatomical and Functional Outcomes—A Report of 16 Cases at the Order of Malta’s Hospital Center
《Open Journal of Orthopedics》2024年第11期478-488,共11页Khalifa Ababacar Faye Alioune Badara Gueye Mouhamadou Moustapha Niane Charles Alain Valerie Kinkpe 
Introduction: Relapsed Congenital Talipes Equino Varus (CTEV) refers to clubfoot diagnosed after walking age. We refer to this entity as residual deformities of a previously treated clubfoot or a complete recurrence f...
关键词：CLUBFOOT RELAPSED DISTRACTION ILIZAROV 
Realgar-indigo naturalis formula for the treatment of patients with relapsed and arsenic trioxide-resistant acute promyelocytic leukemia:A case series
《Journal of Integrative Medicine》2024年第5期614-620,共7页Yong-guang Fang Shi-lin Huang Nan-nan Chen 
Introduction There is currently no standard treatment for relapsed and arsenic trioxide(ATO)-resistant acute promyelocytic leukemia(APL).Here,we report a case series of realgar-indigo naturalis formula(RIF)for the suc...
关键词：Acute promyelocytic leukemia Realgar-indigo naturalis formula Arsenic Trioxide RESISTANT Case report 
Resistance mechanisms and potential therapeutic strategies in relapsed or refractory natural killer/T cell lymphoma
《Chinese Medical Journal》2024年第19期2308-2324,共17页Chengji Wang Liang Wang 
funded by Beijing Physician Scientist Training Project(No.BJPSTP-2024-01)to Liang Wang.
Natural killer/T cell lymphoma(NKTCL)is a malignant tumor originating from NK or T cells,characterized by its highly aggressive and heterogeneous nature.NKTCL is predominantly associated with Epstein-Barr virus infect...
关键词：Natural killer/T cell lymphoma Epstein-Barr virus Chemotherapy resistance ASPARAGINASE IMMUNOTHERAPY 
Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia
《Blood Science》2024年第3期11-22,共12页Cheng Zhou Jue Li Xiaofan Sun Liang Zhao Huien Zhan Hui Liang Peng Fang Tuo Zhang Qiongzhi He Juan Du Hui Zeng 
supported by the National Natural Science Foundation of China to H.Z.(Grant Nos.81770184,81970143,and 82270167)and L.Z.(Grant No.81800174);the Talent Young Program of Guangdong Province(2021B1515020017),and the Leading Talents Program from The First Affiliated Hospital of Jinan University to H.Z.
Acute myeloid leukemia(AML)is a common hematological malignancy with overall poor prognosis.Exploring novel targets is urgent and necessary to improve the clinical outcome of relapsed and refractory(RR)AML patients.Th...
关键词：Chemotherapy sensitivity HMGCS1 MAPK pathway Relapsed and refractory AML Targeted therapy 
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia:a registry study
《Blood Science》2024年第3期33-41,共9页Mingyuan Sun Qingsong Yin Yang Liang Chunkang Chang Jing Zheng Jian Li Chunyan Ji Huiying Qiu Junmin Li Yuping Gong Sheng Luo Yan Zhang Rumei Chen Zhenwei Shen Zenglian Yue Siyuan Wang Qingmei Shi Jason Yang Jie Jin Jianxiang Wang 
Ivosidenib,an isocitrate dehydrogenase 1(IDH1)inhibitor,has demonstrated clinical benefits in a pivotal study(AG120-C-001)in patients with IDH1-mutated(mIDH1)acute myeloid leukemia(AML).A registry study(CS3010-101:NCT...
关键词：China IDH1 mutation Ivosidenib Relapsed or refractory acute myeloid leukemia 
New sights into new-onset and relapsed minimal change disease post COVID-19 vaccination:A systemic review of the clinical characteristics and underlying pathogenesis
《Rheumatology & Autoimmunity》2024年第3期145-155,共11页Jiarong Liu Gaosi Xu 
National Natural Science Foundation of China,Grand/Award Numbers:81970583 and 82060138;the Natural Science Foundation of Jiangxi Province,Grand/Award Number:20202BABL206025;Kidney Disease Engineering Technology Research Centre Foundation of Jiangxi Province,Grand/Award Number:20164BCD40095.
Background:Minimal change disease(MCD)following coronavirus disease 2019(COVID-19)vaccination has been increasingly reported;however,the clinical characteristics and pathogenesis of patients with MCD have not been tho...
关键词：COVID-19 minimal change disease SARS-CoV-2 VACCINATION 
Chidamide plus prednisone,cyclophosphamide,and thalidomide for relapsed or refractory peripheral T-cell lymphoma:A multicenter phase II trial
《Chinese Medical Journal》2024年第13期1576-1582,共7页Jinhua Liang Li Wang Xiaodong Wang Guohui Cui Jianfeng Zhou Tongyao Xing Kaixin Du Jingyan Xu Luqun Wang Rong Liang Biyun Chen Jian Cheng Haorui Shen Jianyong Li Wei Xu 
National Natural Science Foundation of China(Nos.81770166,81700193,82170186,and 81720108002);Jiangsu Province’s Medical Elite Programme(No.ZDRCA2016022);Project of the National Key Clinical Specialty,the Jiangsu Provincial Special Program of Medical Science(No.BE2017751);National Science and Technology Major Project(No.2018ZX09734007);China Postdoctoral Science Foundation(No.2021M691336);Jiangsu Postdoctoral Science Foundation(No.2021K083A)
Background:Although the treatment of peripheral T-cell lymphoma(PTCL)has undergone advancements during the past several years,the response rate and long-term effects with respect to patients with PTCL remain unsatisfa...
关键词：Peripheral T-cell lymphoma CHIDAMIDE PREDNISONE CYCLOPHOSPHAMIDE THALIDOMIDE All-oral regimen 
Sintilimab(anti-PD-1 antibody)plus chidamide(histone deacetylase inhibitor)in relapsed or refractory extranodal natural killer T-cell lymphoma(SCENT):a phase Ⅰb/Ⅱ study被引量：3
《Signal Transduction and Targeted Therapy》2024年第6期2765-2773,共9页Yan Gao Haixia He Xueping Li Liling Zhang Wei Xu Ru Feng Wenyu Li Yin Xiao Xinxiu Liu Yu Chen Xiaoxiao Wang Bing Bai Huijing Wu Qingqing Cai Zhiming Li Jibin Li Suxia Lin Yanxia He Liqin Ping Cheng Huang Jiaying Mao Xiujin Chen Baitian Zhao Huiqiang Huang 
supported by the National Natural Science Foundation of China(grant numbers 82170188 and 81970176);Guangdong Basic and Applied Basic Research Foundation(grant number 2021A1515110012).
Anti-PD-1 antibodies are a favorable treatment for relapsed or refractory extranodal natural killer T cell lymphoma(RR-ENKTL),however,the complete response(CR)rate and the duration of response(DOR)need to be improved....
关键词：KILLER LYMPHOMA doses 
Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation
《China Medical Abstracts(Internal Medicine)》2024年第2期123-123,共1页卓亚琪 
Objective To investigate the safety and efficacy of donor-derived CD19+or sequential CD19+CD22+chimeric antigen receptor T-cell(CAR-T)therapy in patients with B-cell acute lymphoblastic leukemia(BALL)afterallogeneic h...
关键词：PATIENTS HEMATOPOIETIC LYMPHOBLASTIC 
全选清除导出
共10页<12345678910>
检索报告 对象比较 聚类工具 使用帮助 返回顶部